Biologic patent thickets and terminal disclaimers

14 December 2023 - Spending on biologics in 2021 represented $260 billion or 46% of all spending on prescription drugs in ...

Read more →

Inequitable conduct and invalidation of patents related to FDA regulated products

13 November 2023 - Median brand name drug launch prices increased from $2,115 in 2008 to $180,007 in 2021. ...

Read more →

Ancillary product patents to extend biologic patent life

13 November 2023 - In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic ...

Read more →

US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic

2 October 2023 - A US Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo ...

Read more →

Changes in the number of continuation patents on drugs approved by the FDA

1 August 2023 - Brand name pharmaceutical manufacturers often sustain high prices in the US by obtaining patents that delay generic ...

Read more →

How a drug company made $114 billion by gaming the US patent system

28 January 2023 - AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. ...

Read more →

Patent reform and lower drug prices should be bipartisan priorities

25 January 2023 - As the 118th Congress convenes this month in Washington D.C., many pundits and advocates have little ...

Read more →

Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi (amifampridine) following a favourable Canadian Federal Court of Appeal ruling

17 January 2023 - Medunik Canada is pleased to announce that on 9 January 2023, the Federal Court of Appeal of ...

Read more →

Recent patent reform bills and their implications for prescription drugs

13 January 2022 - In 2022, several bills were introduced in Congress to revamp US intellectual property law.  ...

Read more →

US backs delay to decision on COVID patent waiver extension

6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...

Read more →

US Supreme Court to hear Amgen bid to revive cholesterol drug patents

4 November 2022 - The US Supreme Court on Friday agreed to hear Amgen's bid to revive patents on its ...

Read more →

AbbVie wins appeal in antitrust case over Humira 'patent thicket'

3 August 2022 - A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by ...

Read more →

Characteristics of key patents covering recent FDA approved drugs

1 August 2022 - New drugs are protected by patents that block generic competition and allow manufacturers to charge high prices. ...

Read more →

EFPIA and Vaccines Europe are deeply disappointed about the decision taken by World Trade Organization at the Ministerial Conference to endorse a TRIPS waiver for COVID-19 vaccines

17 June 2022 - Speaking about the waiver, EFPIA Director General, Nathalie Moll said. “The decision is a serious retrograde step ...

Read more →

IP waiver for COVID vaccines is a threat to future innovation

20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...

Read more →